Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Asthma and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-17RB drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-17RB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View IL-17RB Products |
| Gene Delivery | IL-17RB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View IL-17RB Products |
| Benchmark Ab | Anti-IL-17RB (Sequence of Benchmark) Recombinant positive control. |
View IL-17RB Products |
| Validator | IL-17RB siRNA Set For knockdown verification. |
View IL-17RB Products |
| Related Target A | IL-25 (IL-17E) Primary high-affinity ligand for IL-17RB. |
View IL-25 Products |
| Related Target B | IL-17RA Co-receptor forming a heterodimeric complex with IL-17RB. |
View IL-17RA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ligand Blocking Validation | High-purity ECD-Fc fusions optimized for SPR and ELISA binding assays. |
| Cell-Based Functional Assays | Lentivirus-mediated stable cell line generation for complex membrane receptor preservation. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for reliable assay calibration. |
| False Positives | Validated siRNA included for specificity checks and target knockdown confirmation. |
Live IL-17RB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-17RB therapeutics is intensifying, with major players focusing on monoclonal antibodies designed to block the IL-25/IL-17RB axis. As first-generation therapies for severe asthma and Type 2 inflammation reach the clinic, the next wave of R&D is targeting solid tumors, including pancreatic and breast cancers, where IL-17RB overexpression drives metastasis and poor prognosis.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Naked mAb | AstraZeneca, Sanofi | Asthma, Atopic Dermatitis | Ligand Blocking Assay (Need high-purity ECD-Fc) |
| Bispecific Ab | Emerging Biotechs | Oncology (Pancreatic Cancer) | Heterodimer Validation (Need Cross-reactive Abs) |
| ADC | Preclinical Innovators | Solid Tumors | Internalization Assay (Need Lentivirus for cell lines) |